Orthofix Medical (OFIX) Expected to Release Earnings on Wednesday

Orthofix Medical (NASDAQ:OFIX) is expected to release its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect the company to announce earnings of ($0.4099) per share and revenue of $209.2770 million for the quarter. Parties may review the information on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 8:30 AM ET.

Orthofix Medical (NASDAQ:OFIX) last issued its quarterly earnings results on Tuesday, May 5th. The medical device company reported ($0.52) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.16. Orthofix Medical had a negative return on equity of 13.44% and a negative net margin of 7.27%.The company had revenue of $196.71 million for the quarter, compared to analyst estimates of $196.40 million. On average, analysts expect Orthofix Medical to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Orthofix Medical Price Performance

OFIX stock opened at $12.26 on Wednesday. The stock has a market capitalization of $495.55 million, a price-to-earnings ratio of -8.12 and a beta of 0.71. The company has a quick ratio of 1.76, a current ratio of 2.87 and a debt-to-equity ratio of 0.54. Orthofix Medical has a 52-week low of $8.85 and a 52-week high of $16.99. The stock’s fifty day simple moving average is $10.33 and its 200-day simple moving average is $11.89.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on OFIX shares. Canaccord Genuity Group reduced their target price on Orthofix Medical from $20.00 to $18.00 and set a “buy” rating on the stock in a research report on Thursday, May 21st. Stifel Nicolaus lowered their price target on Orthofix Medical from $18.00 to $15.00 and set a “buy” rating for the company in a report on Friday, May 22nd. Wall Street Zen downgraded shares of Orthofix Medical from a “buy” rating to a “hold” rating in a research note on Saturday, May 2nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Orthofix Medical in a research note on Friday, July 17th. Finally, Barrington Research increased their price objective on shares of Orthofix Medical from $15.00 to $17.00 and gave the stock an “outperform” rating in a report on Monday, July 6th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Orthofix Medical has an average rating of “Hold” and a consensus target price of $16.00.

Insider Transactions at Orthofix Medical

In other Orthofix Medical news, Director John B. Henneman III purchased 5,000 shares of Orthofix Medical stock in a transaction on Thursday, May 7th. The shares were purchased at an average cost of $12.26 per share, with a total value of $61,300.00. Following the completion of the transaction, the director directly owned 90,809 shares in the company, valued at approximately $1,113,318.34. This represents a 5.83% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Aviva Mcpherron sold 3,670 shares of Orthofix Medical stock in a transaction on Thursday, June 18th. The shares were sold at an average price of $9.38, for a total transaction of $34,424.60. Following the transaction, the insider owned 66,330 shares in the company, valued at $622,175.40. The trade was a 5.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders bought 189,896 shares of company stock worth $2,293,970. 2.70% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in OFIX. Paradigm Capital Management Inc. NY grew its holdings in Orthofix Medical by 34.6% during the 2nd quarter. Paradigm Capital Management Inc. NY now owns 3,340,600 shares of the medical device company’s stock valued at $37,248,000 after purchasing an additional 858,900 shares in the last quarter. Millennium Management LLC lifted its holdings in Orthofix Medical by 86.6% in the 3rd quarter. Millennium Management LLC now owns 1,475,718 shares of the medical device company’s stock worth $21,605,000 after buying an additional 684,850 shares in the last quarter. Bank of America Corp DE lifted its holdings in Orthofix Medical by 659.5% in the 2nd quarter. Bank of America Corp DE now owns 687,410 shares of the medical device company’s stock worth $7,665,000 after buying an additional 596,907 shares in the last quarter. Arrowstreet Capital Limited Partnership boosted its position in Orthofix Medical by 1,670.1% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 310,645 shares of the medical device company’s stock valued at $4,548,000 after buying an additional 293,095 shares during the last quarter. Finally, Qube Research & Technologies Ltd boosted its position in Orthofix Medical by 179.4% in the 2nd quarter. Qube Research & Technologies Ltd now owns 163,192 shares of the medical device company’s stock valued at $1,820,000 after buying an additional 104,778 shares during the last quarter. 89.76% of the stock is currently owned by hedge funds and other institutional investors.

Orthofix Medical Company Profile

Orthofix Medical Inc (NASDAQ: OFIX) is a global medical device company focused on the design and development of innovative orthopedic and spinal solutions. The company’s core business is divided into two segments: spine and orthopedics. In the spine segment, Orthofix offers a range of titanium implants, biologics and portable bone growth stimulation devices designed to support spinal fusion, deformity correction and minimally invasive procedures. Its orthopedic segment encompasses products for fracture fixation, external fixation systems, trauma care and sports medicine, providing surgeons with implantable devices and instruments for complex bone reconstruction and healing.

Orthofix’s product portfolio includes strut systems, bone growth stimulators, interbody fusion devices and fixation hardware that address various indications such as degenerative disc disease, spinal deformities, non-unions and long-bone fractures.